Metsera, Inc. raised $215 million in a Series B funding round led by Wellington Management and Venrock Healthcare Capital Partners to advance its clinical-stage portfolio of peptide therapies.
Metsera, Inc. raised $215 million in a Series B funding round led by Wellington Management and Venrock Healthcare Capital Partners to advance its clinical-stage portfolio of peptide therapies.
11/13/24, 12:06 PM
Location
new yorkMoney raised
$215 million
Industry
biotechnology
health care
Round Type
series b
Investors
Sym Biosis, Newpath Partners, Soft Bank Vision Fund 2, Gv, Alpha Wave Ventures, Arch Venture Partners, Ra Capital Management, Deep Track Capital, Viking Global Investors, T. Rowe Price Investment Management, Inc., T. Rowe Price Associates, Inc., Janus Henderson Investors, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Wellington Management
Metsera, Inc. has successfully closed a $215 million Series B financing round to further accelerate its innovative portfolio aimed at treating obesity and metabolic diseases. The round was backed by prominent investors including Wellington Management and Venrock Healthcare Capital Partners, alongside several new and existing investors.
Company Info
Location
new york, new york, united states
Additional Info
Founded in 2022 by Population Health Partners and ARCH Venture Partners, Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases. Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.